Study
| Phase III, randomized, controlled study (SWOG S1826) |
| Previously untreated pts were ≥12 years (y) with stage 3-4 HL |
| N-AVD (n=489) vs. BV-AVD (n=487) |
Efficacy
| 1-year EFS: 91% vs 84%, HR:0.56, p=0.0019 |
| 1-year OS: 99% vs 98% |
Safety
| Grade≥3 AEs: Neutropenia (47% vs 25%), anemia (6% vs 9%), peripheral sensory neuropathy (1% vs 8%) |
Journal of Clin Oncol 2023 41:17_suppl, LBA4-LBA4
http://doi.org/10.1200/JCO.2023.41.17_suppl.LBA4
Reviewed by Elvin Chalabiyev, MD on Jun 24, 2023
